Senseonics Holdings Inc (NYSE:SENS) stock has reached a 52-week high, trading at $0.76, marking a significant milestone for the company. According to InvestingPro data, the stock's current valuation appears elevated compared to its Fair Value, with analysts setting price targets ranging from $0.30 to $2.50. While recent momentum has been strong, with notable gains over the past three months, InvestingPro analysis reveals some underlying challenges. The company faces weak gross profit margins and is not currently profitable, with a negative EBITDA of $76.2 million in the last twelve months. Despite these headwinds, the company maintains a healthy liquidity position with a current ratio of 2.47. InvestingPro subscribers have access to 8 additional key insights and a comprehensive Pro Research Report, offering deeper analysis of SENS's financial health and growth prospects.
In other recent news, medical technology firm Senseonics reported its Q3 results, highlighting a decrease in net revenue to $4.3 million, down from $6.1 million year-over-year. Despite a net loss for the quarter, the company anticipates a stronger performance with the recent FDA approval of its Eversense 365 product, the first one-year continuous glucose monitor (CGM). A full revenue impact from this product is expected in Q1 2025.
Furthermore, Senseonics has begun a partnership with Mercy Health System for Eversense 365 and is implementing restructuring efforts to reduce operating expenses by over $10 million in 2025. The company also projects a doubling of new patient starts and a 50% increase in the global installed base for the full year 2024.
Despite a gross loss in Q3 2024 of $4.1 million, Senseonics remains optimistic, with early feedback on Eversense 365 being positive. The company has also strengthened its financial position with $74.8 million in cash, allowing for debt repayment and extended cash runway into late 2025. These are among the recent developments in the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.